Biopharmaceutical company and leader in pulmonary arterial hypertension (PAH) therapeutics, Actelion Ltd., has just announced it has filed a New Drug Application (NDA) with the US Food and Drug Administration for innovative PAH treatment Uptravi® (selexipag) — the first oral…
News
United Therapeutics Corporation recently announced that Medtronic, Inc., the world’s third largest medical device company, has forwarded a pre-market approval application to the U.S. Food and Drug Administration (FDA) for their proprietary SynchroMed® II implantable drug infusion system, along with a new catheter, to be used with United Therapeutics’s Remodulin® (treprostinil) injectable, formulated for intravenous treatment of…
The Pulmonary Hypertension Association, one of the country’s most prominent non-profit support, education, advocacy and awareness associations, has just launched a series of online PH learning materials for the holidays, titled, “12 Days of PHA Resources.” According to the PHA, it is common for PH patients to…
Specialized care for those with Pulmonary Hypertension continues to improve across America, with an increasing number of physicians and clinics that are designed to give those with PH the therapy and guidance needed to increase quality of life while living with the disease. Most recently, Kentuckiana Pulmonary Associates of Louisville…
Late-stage cell therapy company Cytori Therapeutics, Inc. will host an informational session about its pivotal STAR clinical trial, which aims to expand knowledge about scleroderma and test a potential treatment for the disease. The company, which is currently developing autologous cell therapies from adipose tissue, will use the information session on January…
Popular online shopping destination eBay, through its subsidiary, eBay, Inc. Foundation, recently awarded the Pulmonary Hypertension Association (PHA) a grant worth $3,000 to help bring patients with pulmonary hypertension (PH) to the association’s next Biennial International Conference and Scientific Sessions. The 2014 sessions took place from June 20-22 in Indianapolis, Indiana,…
A nursing researcher at Louisiana State University Health Sciences Center School of Nursing in New Orleans has found that many factors can impact the quality of life in people with pulmonary hypertension (PH), including mood, anxiety, stress, walking, and the availability of social support. PH is a chronic disease…
An international collaboration of researchers from the United States and China reported that adiponectin (APN), a protein that regulates glucose levels and fatty acid breakdown in the body, may be a naturally-occurring anti-fibrotic agent for systemic sclerosis (SSc). They presented their study at the 2014 American College of Rheumatology Meeting…
Findings from a study entitled “Right ventricular adaptation to pulmonary pressure load in patients with chronic thromboembolic pulmonary hypertension before and after successful pulmonary endarterectomy — a cardiovascular magnetic resonance study,” were recently published in the Journal of Cardiovascular Magnetic Resonance. Chronic thrombolic pulmonary hypertension (CTEPH)…
On Dec 10, 2014 iBio, Inc. revealed progress in developing IBIO-CFB03, a treatment for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases at its Annual Meeting. Unlike other proteins, which are produced by animals or cells in a dish, IBIO-CFB03 will be grown in plants. IPF is a…
GlaxoSmithKline (GSK) recently announced it has applied for a European Medicines Agency (EMA) variation to the Marketing Authorization for ambrisentan (Volibris®), in order to expand the currently approved indication to include its use as a first-line combination therapy with tadalafil for pulmonary arterial hypertension (PAH). Ambrisentan is classified as a…
Silence Therapeutics recently developed a genetic toolkit to support the company’s research into to several diseases, including pulmonary arterial hypertension (PAH). Specifically, Silence will utilize its new genetic toolkit to modulate gene expression and deliver unique systems to a variety of organs and cell types in pre-clinical in vivo animal…
